Novo Nordisk trims its U.S. workforce amid surging demand for diabetes and obesity drugs, reflecting broader changes in pharmaceutical manufacturing.
Novo Nordisk resubmits Awiqli for FDA review, aiming to revolutionize type 2 diabetes treatment with once-weekly insulin dosing.
Sign in to your account
Remember me